Citadel Advisors
TERN

Citadel Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Citadel Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3M Buy
328,700
+235,000
+251% +$9.65M ﹤0.01% 2502
2025
Q4 		$3.79M Buy
93,700
+79,500
+560% +$1.84M ﹤0.01% 4760
2025
Q3 		$107K Sell
14,200
-75,300
-84% -$481K ﹤0.01% 11804
2025
Q2 		$334K Sell
89,500
-43,100
-33% -$135K ﹤0.01% 9551
2025
Q1 		$366K Buy
132,600
+57,000
+75% +$233K ﹤0.01% 9146
2024
Q4 		$419K Sell
75,600
-155,100
-67% -$1.05M ﹤0.01% 8956
2024
Q3 		$1.92M Buy
230,700
+205,300
+808% +$1.69M ﹤0.01% 5615
2024
Q2 		$173K Buy
25,400
+6,200
+32% +$37.6K ﹤0.01% 10142
2024
Q1 		$126K Buy
19,200
+4,900
+34% +$32K ﹤0.01% 11044
2023
Q4 		$92.8K Buy
14,300
+400
+3% +$2.12K ﹤0.01% 11028
2023
Q3 		$69.9K Sell
13,900
-12,100
-47% -$76.8K ﹤0.01% 11329
2023
Q2 		$228K Buy
+26,000
New +$303K ﹤0.01% 9602

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's TERN Position: Q1 2026 in Review

Citadel Advisors increased its Terns Pharmaceuticals (TERN) stake by 1.6% in Q1 2026, buying an estimated $2.14M and bringing the position to 3,218,810 shares worth $170M. The position accounts for 0.03% of the portfolio, ranked #520.

Citadel Advisors first reported a position in TERN in Q1 2021 and has held it in 17 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Citadel Advisors held 3,218,810 shares of Terns Pharmaceuticals worth $170M as of Q1 2026.
  • Citadel Advisors bought 52,168 Terns Pharmaceuticals shares in Q1 2026, an estimated $2.14M.
  • Terns Pharmaceuticals made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #520 holding.
  • Citadel Advisors first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.